[Paclitaxel containing chemotherapeutic regimens in first line and reintroduced palliative treatment of metastatic cervical cancer]. / Paklitaxeltartalmú kemoterápiás kombináció metasztatikus cervixtumor elso vonali és reindukciós palliatív kezelésében.

ABSTRACT

INTRODUCTION: The paclitaxel-carboplatin doublet is an alternative choice in the first line treatment of metastatic or recurrent cervical cancer according to international guidelines. METHOD: The history of seven patients treated with paclitaxel-platinum in the last three years in the Petz Aladár Hospital is reported. A case report, supporting the efficacy of the combination in emergency and in reintroduced settings is presented as well. RESULTS: The average progression-free survival was 10 months. All patients were alive at the time of the submission of the article. CONCLUSION: The results confirm the efficacy of the paclitaxel-carboplatin AUC 5 and the paclitaxel-cisplatin combinations in the treatment of metastatic cervical cancer. Orv Hetil. 2018; 159(24) 974-977.